# Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196

> **NCT03220165** · PHASE1 · COMPLETED · sponsor: **Madrigal Pharmaceuticals, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MGL-3196

## Key facts

- **NCT ID:** NCT03220165
- **Lead sponsor:** Madrigal Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-06
- **Primary completion:** 2017-09-03
- **Final completion:** 2017-09-03
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2017-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03220165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03220165, "Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03220165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*